Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Assumed conversion of 2031 Notes Assumed Conversion Of Two Thousand Thirty One Notes [Member] Assumed conversion of 2031 Notes Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Potential Fixed Monetary Amount, Total Potential Milestone Fixed Monetary Settlement Amount Potential milestone fixed monetary settlement amount. Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument Financial Instrument [Axis] Accrued compensation and benefits Employee-related Liabilities, Current Variable Rate, Closing Date Through Seventh Anniversary Variable Rate, Seventh Anniversary [Member] Variable Rate, Seventh Anniversary Two Thousand Twenty Six Shelf Registration Statement and ATM Agreement Two Thousand Twenty Six Shelf Registration Statement and ATM Agreement [Member] Two Thousand Twenty Six Shelf Registration Statement and ATM Agreement Leases Lessee, Finance Leases [Text Block] Initial conversion (in dollars per share) Debt Instrument, Convertible, Conversion Price Consolidated Entities [Axis] Consolidated Entities [Axis] Agreed-upon Purchase Price per Share (in dollars per share) Shares acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Project [Axis] Project [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Net loss Net Income (Loss) Excluding Redeemable Noncontrolling Interests Net Income (Loss) Net income (loss) excluding redeemable noncontrolling interests net income (loss). Leases [Abstract] Leases [Abstract] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Percentage of ownership reduced for private equity financing Percentage of Ownership Reduced for Private Equity Financing Percentage of ownership reduced for private equity financing. Consolidated Entities Consolidated Entities [Domain] Convertible preferred stock, threshold consecutive trading days Convertible Preferred Stock, Threshold Consecutive Trading Days Convertible Preferred Stock, Threshold Consecutive Trading Days Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current EMEA EMEA [Member] Concentration Risk [Table] Concentration Risk [Table] Redeemable convertible noncontrolling interests Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests Temporary equity carrying amount net including portion attributable to noncontrolling interests Adjustments to additional paid in capital related to premium payments Adjustments To Additional Paid In Capital, Decrease From Premium Payments Payments Adjustments to additional paid in capital related to premium payments. Entity Address, City or Town Entity Address, City or Town Percentage of royalty interest payments on net sales Percentage of Royalty Interest Payments on Net Sales Percentage of royalty interest payments on net sales. Number of product candidates in late development Number of Product Candidates In Late Development Number of Product Candidates In Late Development Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Bayer Bayer [Member] Bayer . 2025 Note Offering 2025 Note Offering [Member] 2025 Note Offering Series A Cumulative Convertible Participating Preferred Stock Series A Cumulative Convertible Participating Preferred Stock [Member] Series A Cumulative Convertible Participating Preferred Stock Net product revenue Product [Member] Royalties on net product revenue Royalty Expense Total Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Proceeds from special cash dividends received from an investment in equity securities Proceeds from Equity Method Investment, Distribution, Return of Capital Proceeds from common stock issuances under ESPP Proceeds from Stock Plans Level 2 Fair Value, Inputs, Level 2 [Member] Other income (expense), net: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Unvested market-based RSUs Unvested Market Based Restricted Stock Unit [Member] Unvested market-based restricted stock unit. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Unrealized Losses Cash Equivalents Unrealized Losses Cash Equivalents Unrealized Losses Revenue Benchmark Revenue Benchmark [Member] License License [Member] U.S. UNITED STATES Subsequent Event Type [Axis] Subsequent Event Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Payments for option indexed to issuer's equity Payments For Option Indexed To Issuer's Equity Payments For Option Indexed To Issuer's Equity Schedule of Segment Information for Revenue, Significant Operating Expenses and Other Income (Expense), and Net Loss Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Transition Service Agreement And Sublease Agreement Transition Service Agreement And Sublease Agreement [Member] Transition service agreement and sublease agreement. Related Party Related and Nonrelated Parties [Axis] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Repayment of term loans Repayments of Lines of Credit Deferred royalty obligations, net Deferred royalty obligations, net Deferred Royalty Obligation, Net Deferred royalty obligation, net. Royalty interest payments may adjust to maximum rate Royalty Interest Payments May Adjust to Maximum Rate Royalty interest payments may adjust to maximum rate. Proceeds from debt, net of issuance costs Proceeds from Debt, Net of Issuance Costs Schedule of Future Minimum Lease Payments for Noncancelable Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Customer D Customer D [Member] Customer D. Variable Rate, Triggering Event Variable Rate, Triggering Event [Member] Variable Rate, Triggering Event Preferred stock, outstanding (in shares) Beginning balance (in shares) Ending Balance (in shares) Preferred Stock, Shares Outstanding Aggregate Face Values Aggregate principal amount Debt Instrument, Face Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Expected life of notes Debt Instrument, Term Treasury stock, at cost; 7,597,172 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 Treasury Stock, Common, Value Effective interest rate Debt Instrument, Interest Rate, Effective Percentage 2027 Notes Initial Purchasers 2027 Notes Initial Purchasers [Member] 2027 Notes Initial Purchasers Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Operating lease liabilities, current portion Operating Lease, Liability, Current Cash And Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] BridgeBio Oncology Therapeutics, Inc. BridgeBio Oncology Therapeutics, Inc. [Member] BridgeBio Oncology Therapeutics, Inc. Net Loss Per Share Earnings Per Share [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Option indexed to issuer's equity, strike price (in dollars per share) Option Indexed to Issuer's Equity, Strike Price Company Selected Measure Name Company Selected Measure Name Sale of Stock [Domain] Sale of Stock [Domain] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Concentration Risk [Line Items] Concentration Risk [Line Items] Maximum amount of stock remaining eligible to be sold Sale of Stock, Stock Remaining Eligible To Be Sold, Amount Sale of Stock, maximum amount of stock remaining eligible to be sold. Funding Agreement Funding Agreement [Member] Funding Agreement. Deferred Royalty Obligations, Net Deferred Royalty Obligations, Net [Text Block] Deferred royalty obligations, net. Credit Facility [Domain] Credit Facility [Domain] Operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Assumed conversion of 2029 Notes Assumed Conversion Of Two Thousand Twenty Nine Notes [Member] Assumed conversion of two thousand twenty nine notes. Accrued cash dividends on preferred stock Dividends Payable, Current Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Accrued cash dividends Dividends Payable Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Debt Conversion Terms Two Debt Conversion Terms Two [Member] Debt Conversion Terms Two Internal pre-tax rate Convertible Preferred Stock, Redemption Price, Internal Pre-Tax Rate Convertible Preferred Stock, Redemption Price, Internal Pre-Tax Rate Operating cash flows for operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Project [Domain] Project [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Deferred Royalty Obligations, Net Schedule Of Deferred Royalty Obligations, Net [Table Text Block] Schedule of deferred royalty obligations, net. Schedule of Concentration, Percentage of Gross Revenues Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Conversion rate (in shares) Debt Instrument, Convertible, Conversion Ratio Marketable securities: Debt Securities [Abstract] Encaleret for ADH1 Encaleret for ADH1 [Member] Encaleret for ADH1. Operating lease liabilities Increase (Decrease) in Operating Lease Liability Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Accrued Amount, Cash or stock at our sole discretion Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion Potential milestone accrued amount settlement in cash or stock at sole discretion. Antidilutive Securities Antidilutive Securities [Axis] Transfers from (to) noncontrolling interests Temporary Equity, Transfer (To) From Noncontrolling Interest Temporary equity transfer (to) from noncontrolling interest. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Concentration Risk Type [Domain] Concentration Risk Type [Domain] Debt instrument, conversion, equivalent (in shares) Debt Instrument, Convertible, Number of Equity Instruments Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Royalty revenue Royalty [Member] Debt Instrument, Name Debt Instrument, Name [Domain] Expiration Date Trading Arrangement Expiration Date Deferred Royalty Obligations, net Deferred Royalty Obligations, Net [Policy Text Block] Deferred Royalty Obligations, Net 2030 Long-Term Debt, Maturity, Year Four Total cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Total stockholders’ deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Incremental Term Loan Incremental Term Loan [Member] Incremental term loan. Assumed conversion of 2027 Notes Assumed Conversion Of Two Thousand Twenty Seven Notes [Member] Assumed conversion of two thousand twenty seven notes. Share repurchase program, liability Share Repurchase Program, Liability Share Repurchase Program, Liability Investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Proceeds from royalty obligation under funding agreement Proceeds from Royalty Obligation Under Funding Agreement Proceeds from royalty obligation under funding agreement. Maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Segments [Domain] Segments [Domain] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Debt Debt Disclosure [Text Block] Debt issuance costs including initial purchasers discounts, legal and other professional fees Debt Issuance Costs, Net 2029 Notes, net 2029 Convertible Notes 2029 Convertible Senior Notes [Member] Two Point Two Five Percentage Convertible Senior Notes Due Two Thousand And Twenty Nine [Member] Funding payment received, net of certain transaction expenses Funding Payment Received Net of Certain Transaction Expenses Funding payment received net of certain transaction expenses. PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Secured Debt Secured Debt [Member] Change in fair value of the embedded derivative associated with the deferred royalty obligation Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Total operating costs and expenses Costs and Expenses Thereafter Long-Term Debt, Maturity, after Year Five Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Total BridgeBio stockholders’ deficit Beginning balance Ending balance Equity, Attributable to Parent Transition Service Aggrement Transition Service Aggrement [Member] Transition service aggrement. Assets Assets [Abstract] Amortized Cost Basis Debt Securities, Available-for-Sale, Amortized Cost Insider Trading Policies and Procedures [Line Items] Milestone payments Potential Milestone Payments Potential milestone payments. Debt instrument, increase in conversion rate, number of shares issuable (in shares) Debt Instrument, Convertible, Increase In Conversion Rate, Number Of Common Stock Issuable Debt instrument, convertible, increase in conversion rate, number of common stock issuable. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Restructuring, impairment, and related charges Restructuring, Settlement and Impairment Provisions Aggregate purchase price Sale of Stock, Consideration Received Per Transaction Antidilutive securities excluded from computation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Entity Central Index Key Entity Central Index Key Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Notice period for termination of agreement Contract With Customer, Termination of Agreement, Notice Period Notice period for termination of agreement. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] 2021 Note Offering 2021 Note Offering [Member] 2021 Note Offering Investment, Name Investment, Name [Axis] Preferred stock, dividend rate, percentage Preferred Stock, Dividend Rate, Percentage Cost of license, services, and royalty revenue License, Services and Royalty [Member] Cost of license, services and royalty revenue. Proceeds from royalty obligation under interest purchase and sale agreement Proceeds From Royalty Obligation Under Interest Purchase and Sale Agreement Proceeds from royalty obligation under interest purchase and sale agreement. 2031 Notes Initial Purchasers 2031 Notes Initial Purchasers [Member] 2031 Notes Initial Purchasers Common stock options issued and outstanding Common Stock Options Issued And Outstanding [Member] Common stock options issued and outstanding. Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Assumed conversion of Preferred Stock Assumed Conversion of Preferred Stock [Member] Assumed Conversion of Preferred Stock Variable Conversion Price Component [Axis] Variable Conversion Price Component [Axis] Variable Conversion Price Component Intangible Assets, net Intangible Asset [Text Block] Statement [Line Items] Statement [Line Items] Total assets Assets Convertible Debt Convertible Debt [Member] Schedule of Cash Equivalent and Marketable Securities Schedule Of Cash Equivalents And Marketable Securities [Table Text Block] Schedule of cash equivalents and marketable securities. Interest expense Interest Expense, Nonoperating Schedule of Stock Based Compensation for Employees and Non Employees Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Compensation Share-Based Payment Arrangement [Text Block] PEO PEO [Member] Total principal amount Long-Term Debt, Maturity, Total Principal Amount Long-Term Debt, Maturity, Total Principal Amount 2028 Long-Term Debt, Maturity, Year Two Other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Deferred royalty obligations, current portion Deferred Royalty Obligations, Current Deferred royalty obligations. Accumulated Deficit Retained Earnings [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Operating expenses Operating Expenses Money market funds Money Market Funds [Member] Operating lease, impairment loss Operating Lease, Impairment Loss Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] License and services revenue License and Service [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share) Earnings Per Share, Diluted Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Amortization expenses Intangible Asset, Finite-Lived, Amortization Expense Deferred Royalty Obligations [Abstract] Deferred Royalty Obligations [Abstract] Deferred royalty obligations. Variable Conversion Price, On And After Fifth Anniversary Variable Conversion Price, On And After Fifth Anniversary [Member] Variable Conversion Price, On And After Fifth Anniversary Total revenues, net Revenue Revenue from Contract with Customer, Excluding Assessed Tax Accrued research and development liabilities Accrued Research And Development Liabilities, Current Accrued research and development liabilities current. Repurchase of common stock Stock Repurchased During Period, Value Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Unrealized Gains Cash Equivalents Unrealized Gains Cash equivalents unrealized gains. 2029 Notes Initial Purchasers 2029 Notes Initial Purchasers [Member] 2029 Notes Initial Purchasers Cash, Cash Equivalents, Marketable Securities, and Restricted Cash Cash, Cash Equivalents, Marketable Securities and Restricted Cash [Policy Text Block] Cash, Cash Equivalents, Marketable Securities and Restricted Cash Royalty agreement, amortization of debt issuance costs and discounts Royalty Agreement, Amortization of Debt Issuance Costs and Discounts Royalty Agreement, Amortization of Debt Issuance Costs and Discounts Infigratinib for achondroplasia and hypochondroplasia Infigratinib for achondroplasia and hypochondroplasia [Member] Infigratinib. Schedule of Maturities of Long-Term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule Of Equity Method Investments [Table] Equity Method Investment [Table] Sale of Stock [Axis] Sale of Stock [Axis] Royalty Interest Purchase and Sale Agreement Royalty Interest Purchase And Sale Agreement [Member] Royalty interest purchase and sale agreement. Loss from operations Operating Income (Loss) Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Beneficial ownership limitation percentage Convertible Preferred Stock, Beneficial Ownership Limitation, Percentage Convertible Preferred Stock, Beneficial Ownership Limitation, Percentage Schedule Of Employees And Non Employees Service Share Based Compensation [Table] Schedule Of Employees And Non Employees Service Share Based Compensation [Table] Schedule of employees and non-employees service share-based compensation. Preferred stock dividends Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Estimated shares issuable under performance-based milestone compensation arrangements Estimated Shares Issuable Performance Based Milestone Compensation Arrangement [Member] Estimated shares issuable performance based milestone compensation arrangement. Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Convertible preferred stock, threshold trading days Convertible Preferred Stock, Threshold Trading Days Convertible Preferred Stock, Threshold Trading Days Common stock, issued (in shares) Common Stock, Shares, Issued Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Finished goods Inventory, Finished Goods, Gross Marketable securities Debt Securities, Available-for-Sale, Current Charles Homcy [Member] Charles Homcy Accounts receivable, net Increase (Decrease) in Accounts Receivable Total cash equivalents and marketable securities, amortized cost basis Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Cash Equivalents, at Carrying Value And Debt Securities, Available-For-Sale, Amortized Cost Product and Service Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Non-royalty revenue, percentage of revenue from sublicensees, term Non-Royalty Revenue, Percentage of Revenue From Sublicensees, Term Non-Royalty Revenue, Percentage of Revenue From Sublicensees, Term Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Other current liabilities Total other current liabilities Other Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Other research programs Other Research Programs [Member] Other research programs. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Accrued Amount, Stock Potential Milestone Accrued Amount Settlement In Stock Potential milestone accrued amount settlement in stock. Gross amount Intangible Asset, Finite-Lived, before Accumulated Amortization Finance lease, impairment loss Finance Lease, Impairment Loss Net loss from equity method investments Net loss from equity method investments Loss from equity method investment Income (Loss) from Equity Method Investments 2021 Capped Call Transactions 2021 Capped Call Transactions [Member] Two thousand twenty one capped call transactions. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Potential Fixed Monetary Amount, Stock Potential Milestone Fixed Monetary Amount Settlement In Stock Potential milestone fixed monetary amount settlement in stock. Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] All Award Types Award Type [Domain] Finance lease costs Finance Lease, Interest Expense Remainder of 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair Value Measurements Fair Value Disclosures [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Stock repurchased during period, (in shares) Treasury Stock, Shares, Acquired Finite-lived intangible asset, expected amortization, year one Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Debt instrument, convertible, threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Geographical [Axis] Geographical [Axis] Contract with customer, liability Contract with Customer, Liability Percentage of underwriters commissions Percentage of Commissions on Gross Proceeds of Sales of Common Stock Percentage of underwriters commissions on gross proceeds of sales of common stock Legal Entity Legal Entity [Axis] Total interest and amortization expense Interest expense Interest Expense, Debt Net Proceeds Used Stock repurchased, value Treasury Stock, Value, Acquired, Cost Method Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued professional services Accrued Professional Fees, Current Regulatory and sales milestone payments eligible to receive Revenue, Remaining Performance Obligation, Maximum Eligible Milestone Payment Regulatory and Sales Milestone Payments Eligible to Receive. Non-NEOs Non-NEOs [Member] Equity ownership percentage approximately Equity Method Investment, Ownership Percentage Finite-lived intangible asset, expected amortization, year two Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Schedule of Total Interest Expense Recognized and Effective Interest Related to Notes Schedule Of Interest Expense Recognized And Effective Interest Rates Related To Notes [Table Text Block] Schedule of interest expense recognized and effective interest rates related to notes. Revenue, remaining performance obligation, upfront payment Revenue, Remaining Performance Obligation, Upfront Payment Revenue, Remaining Performance Obligation, Upfront Payment Investment, Name Investment, Name [Domain] Customer [Domain] Customer [Domain] Schedule of Inventories Presented on Condensed Consolidated Balance Sheet Schedule of Inventory, Current [Table Text Block] Leases Lessee, Operating Leases [Text Block] 2027 Long-Term Debt, Maturity, Year One Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Undesignated Preferred Stock Undesignated Preferred Stock [Member] Undesignated Preferred Stock Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Raw materials Inventory, Raw Materials, Gross Repurchase of common stock Repurchase of common stock Payments for Repurchase of Common Stock Deferred revenue, current portion Contract with Customer, Liability, Current Statistical Measurement Statistical Measurement [Axis] Preferred stock dividends Dividends, Preferred Stock, Stock Total cost of revenues Cost of Revenue Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Product and Service Product and Service [Axis] Aggregate minimum commitment Aggregate Minimum Commitment Aggregate minimum commitment. Debt instrument, convertible, threshold trading days Debt Instrument, Convertible, Threshold Trading Days Restricted cash — Included in “Other assets” Restricted Cash, Noncurrent Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Unvested performance-based RSUs Unvested Performance Based Restricted Stock Unit [Member] Unvested performance-based restricted stock unit. Total marketable securities Estimated Fair Value Debt Securities, Available-for-Sale Straight-line operating lease costs Operating Lease, Cost Contractual interest expense Interest Expense, Debt, Excluding Amortization Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Annual net sales Annual Net Sales, Threshold Annual net sales. Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit Liabilities and Equity Variable lease costs Variable Lease, Cost Other development programs Other Development Programs [Member] Other development programs. Employee Stock Option Share-Based Payment Arrangement, Option [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party Related and Nonrelated Parties [Domain] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Tabular List, Table Tabular List [Table Text Block] Additional paid-in capital Additional Paid in Capital Payment for intangible assets Payments to Acquire Intangible Assets Amended Loan Agreement Amended Loan Agreement [Member] Amended Loan Agreement Finite-lived intangible asset, expected amortization, year three Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Amortization expenses, remainder period of 2026 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Name Awards Close in Time to MNPI Disclosures, Individual Name Variable Rate, Change of Control Transaction Variable Rate, Change of Control Transaction [Member] Variable Rate, Change of Control Transaction Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Schedule of Other Current Liabilities Other Current Liabilities [Table Text Block] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Cash equivalents: Cash And Cash Equivalents Fair Value Disclosure [Abstract] Cash and cash equivalents fair value disclosure. Preferred stock dividends and accretion Preferred Stock Dividends and Other Adjustments Undesignated preferred stock and Series A preferred stock Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Cost of Revenues Cost of Goods and Service [Policy Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Convertible preferred stock, redemption price, maximum number of quarters excluding cash dividend payments Convertible Preferred Stock, Redemption Price, Maximum Number of Quarters Excluding Cash Dividend Payments Convertible Preferred Stock, Redemption Price, Maximum Number of Quarters Excluding Cash Dividend Payments Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Credit Facility [Axis] Credit Facility [Axis] Restructuring, Impairment, and Related Charges Restructuring and Related Activities Disclosure [Text Block] Total financial assets Assets, Fair Value Disclosure Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Additional Paid-In Capital Additional Paid-in Capital [Member] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and Cash Equivalent Company Selected Measure Amount Company Selected Measure Amount Depreciation and amortization Depreciation, Depletion and Amortization Issuance of shares under equity compensation plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture 2031 Long-Term Debt, Maturity, Year Five Non-PEO NEO Non-PEO NEO [Member] Customer Concentration Risk Customer Concentration Risk [Member] Investment Agreement Investment Agreement [Member] Investment Agreement Award Timing Method Award Timing Method [Text Block] Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Net loss attributable to BridgeBio Net loss attributable to BridgeBio Net Income (Loss) Attributable to Parent Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Percentage of principal amount to be repurchased in fundamental change Percentage Of Principal Amount To Be Repurchased In Fundamental Change Percentage of principal amount to be repurchased in fundamental change. 2031 Notes, net 2031 Notes, net 2031 Convertible Senior Notes [Member] One point seven five percentage convertible senior notes due two thousand and thirty one. Financing Agreement Financing Agreement [Member] Financing Agreement. Debt instrument, convertible, threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Percentage of purchase price equal to hard cap Percentage Of Purchase Price Equal To Hard Cap Percentage of purchase price equal to hard cap. Revenues: Revenues [Abstract] Gain for change in fair value of embedded derivative liability Gain (Loss) On Change In Fair Value Of Embedded Derivative Liability Gain (loss) on change in fair value of embedded derivative liability. Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Accrual for repurchase of common stock Repurchase Of Common Stock Incurred But Not Yet Paid Repurchase Of Common Stock Incurred But Not Yet Paid Statistical Measurement Statistical Measurement [Domain] Accrued Amount, Cash Potential Milestone Accrued Amount Settlement In Cash Potential milestone accrued amount settlement in cash. Document Fiscal Year Focus Document Fiscal Year Focus Contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Variable Conversion Price Component [Domain] Variable Conversion Price Component [Domain] Variable Conversion Price Component [Domain] Customer [Axis] Customer [Axis] Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of June 30, 2026, 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Repurchase of RSU shares to satisfy tax withholding Payment, Tax Withholding, Share-Based Payment Arrangement Schedule of Loans Balances Schedule of Long-Term Debt Instruments [Table Text Block] Embedded derivative (included in “Deferred royalty obligations, net”) Fair value of embedded derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Restatement Determination Date Restatement Determination Date Noncash income from an equity method investment Noncash Income (Loss) from Equity Method Investments Noncash Income (Loss) from Equity Method Investments Amendment Flag Amendment Flag Current liabilities: Liabilities, Current [Abstract] Conversion of stock, shares converted (in shares) Conversion of Stock, Shares Converted Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax U.S. Treasury securities US Treasury Bill Securities [Member] Number of customers accounted for more than 10% of concentration risk Number of Customers, Percentage of Concentration Risk Number of customers accounted for more than ten percentage of concentration risk. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Preferred stock, dividend rate, maximum percentage Preferred Stock, Dividend Rate, Maximum Percentage Preferred Stock, Dividend Rate, Maximum Percentage Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Assets Assets, Fair Value Disclosure [Abstract] Initial Term Loan Initial Term Loan [Member] Initial term loan. Share Repurchase Program Share Repurchase Program [Domain] Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Inventory reserve Inventory Valuation Reserves Transfers to noncontrolling interests Transfer to Investments Option indexed to issuer's equity, indexed shares (in shares) Option Indexed to Issuer's Equity, Indexed Shares 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four In-licensing and Other Research and Development Agreements In-Licensing And Other Research And Development Agreements Disclosure [Text Block] In-licensing and other research and development agreements disclosure. Deferred revenue Increase (Decrease) in Deferred Revenue Investors contribution fair value Equity Method Investments, Fair Value Disclosure Option indexed to issuer's equity, cap price per share (in dollars per share) Option Indexed to Issuer's Equity, Cap Price Per Share Debt instrument capped call transaction cap price per share. Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Payment of preferred stock dividends Payment of preferred stock dividends Payments of Ordinary Dividends, Preferred Stock and Preference Stock Class of Stock [Axis] Class of Stock [Axis] Customer B Customer B [Member] Customer B. Net loss attributable to common stockholders of BridgeBio Net Income (Loss) Available to Common Stockholders, Basic Less accumulated amortization Intangible Asset, Finite-Lived, Accumulated Amortization Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] 2027 Notes, net Long-Term Debt, Current Maturities QED Therapeutics, Inc QED Therapeutics Inc. [Member] QED Therapeutics, Inc. Recently Adopted Accounting Pronouncements and New Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Net Loss per Share Attributable to Common Stockholders of BridgeBio Earnings Per Share, Policy [Policy Text Block] Non- controlling Interests Noncontrolling Interest [Member] HCR Purchaser HCR Purchaser [Member] HCR Purchaser Net carrying amount Long-Term Debt Debt instrument, settlement method, minimum cash per $1,000 principal amount Debt Instrument, Settlement Method, Minimum Cash Per $1,000 Principal Amount Debt Instrument, Settlement Method, Minimum Cash Per $1,000 Principal Amount Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Stockholders’ Deficit Equity [Text Block] Operating costs and expenses: Costs and Expenses [Abstract] Security Exchange Name Security Exchange Name Transfers from (to) noncontrolling interests Noncontrolling Interest, Period Increase (Decrease) Issuance of noncontrolling interests Issuance (Repurchase) Of Noncontrolling Interest Issuance (repurchase) of noncontrolling interest. Payment for private equity financing with external investors Payment for Private Equity Financing with External Investors Payment for equity private financing with external investors. Accrued interest Total Interest Payable, Current Segments Segment Reporting, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Royalty agreement, interest expense Royalty Agreement, Interest Expense Royalty Agreement, Interest Expense Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] 2026 Note Offering 2026 Note Offering [Member] 2026 Note Offering License fees License Fees License fees. Unvested RSUs Unvested Restricted Stock Unit [Member] Unvested restricted stock unit. Geographical [Domain] Geographical [Domain] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Percentage of capitalized property and equipment Percentage Of Capitalized Property And Equipment Percentage Of Capitalized Property And Equipment Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Preferred stock, redemption price, additional percentage Convertible Preferred Stock, Redemption Price, Additional Percentage Convertible Preferred Stock, Redemption Price, Additional Percentage Supplemental Disclosures of Noncash Investing and Financing Information: Noncash Investing and Financing Items [Abstract] Principal Long-Term Debt, Gross Variable Rate, Closing Date Through Eighth Anniversary Variable Rate, Eighth Anniversary and End of Each Third Month Thereafter [Member] Variable Rate, Eighth Anniversary and End of Each Third Month Thereafter Reportable Segment Reportable Segment [Member] Reportable Segment Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Entity Emerging Growth Company Entity Emerging Growth Company Total cash equivalents and marketable securities, estimated fair value Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available-for-Sale, Fair Value Disclosure Underlying Security Market Price Change Underlying Security Market Price Change, Percent Commercial paper Commercial Paper [Member] Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Royalty purchase agreement, proceeds from sale Royalty Purchase Agreement, Proceeds From Sale Royalty Purchase Agreement, Proceeds From Sale Agency discount notes Agency Discount Notes [Member] Agency discount notes. Cost of revenues: Cost of Revenue [Abstract] Restricted cash — Included in “Prepaid expenses and other current assets” Restricted Cash, Current Treasury Stock Treasury Stock, Common [Member] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Potential Fixed Monetary Amount, Cash Potential Milestone Fixed Monetary Amount Settlement In Cash Potential milestone fixed monetary amount settlement in cash. 2027 Notes, net 2027 Convertible Notes 2027 Convertible Senior Notes [Member] Two point five zero percentage convertible senior notes due two thousand and twenty seven. Deferred Royalty Obligations [Line Items] Deferred Royalty Obligations [Line Items] Deferred Royalty Obligations. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Revenue, remaining performance obligation, regulatory milestone payment Revenue, Remaining Performance Obligation, Regulatory Milestone Payment Revenue, Remaining Performance Obligation, Regulatory Milestone Payment Temporary equity, beginning balance Temporary equity, ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Reconciliation of Cash, Cash Equivalents and Restricted Cash: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Initial conversion price (in dollars per share) Preferred Stock, Convertible, Conversion Price Proceeds from royalty obligation under Royalty Purchase Agreement (as described in Note 9) Proceeds From Royalty Obligation Proceeds from royalty obligation under royalty purchase agreement. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Employee And Non Employee Service Share Based Compensation [Line Items] Employee And Non Employee Service Share Based Compensation [Line Items] Employee and non-employee service share based compensation. 2020 Note Offering 2020 Note Offering [Member] 2020 Note Offering Schedule of Recognized Intangible Assets Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block] Income Statement Location Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Customer A Customer A [Member] Customer A. Schedule Of Interest Payable Note Schedule Of Interest Payable [Table Text Block] Schedule Of Interest Payable Preferred stock dividends and accretion Other Preferred Stock Dividends and Adjustments Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Rest of World Rest of World [Member] Rest of World [Member] Common stock, authorized (in shares) Common Stock, Shares Authorized Weighted-average Estimated Useful Lives Intangible Asset, Finite-Lived, Useful Life Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement. Exercise Price Award Exercise Price Schedule Of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Two Thousand Twenty Six Share Repurchase Program Two Thousand Twenty Six Share Repurchase Program [Member] Two Thousand Twenty Six Share Repurchase Program Repayment of term loans Repayments of Long-Term Debt Unamortized debt discount and issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity method investments Equity Method Investments Equity Component Equity Component [Domain] Preferred stock, expected redemption period Preferred Stock, Expected Redemption Period Preferred Stock, Expected Redemption Period Accrued cash dividends on preferred stock Dividends on Preferred Stock Incurred But Not Yet Paid Dividends on Preferred Stock Incurred But Not Yet Paid Adoption Date Trading Arrangement Adoption Date Inventories Inventory, Policy [Policy Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Total other expense, net Nonoperating Income (Expense) Preferred stock, interest rate, effective percentage Preferred Stock, Interest Rate, Effective Percentage Preferred Stock, Interest Rate, Effective Percentage Proceeds from exercise of remaining portion of option to purchase additional notes Debt Instrument, Option To Purchase Additional Notes, Remaining Portion Exercised Debt instrument, option to purchase additional notes remaining portion exercised. Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion [Axis] Debt Instrument, Convertible Terms Of Conversion Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total Operating Lease, Liability Issuance costs associated with preferred stock Payments of stock issuance costs Payments of Stock Issuance Costs Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Variable Conversion Price, Closing Date Variable Conversion Price, Closing Date [Member] Variable Conversion Price, Closing Date Selling, general and administrative Selling, General and Administrative Expense Variable Redemption, After Fourth Anniversary Variable Redemption, After Fourth Anniversary [Member] Variable Redemption, After Fourth Anniversary Royalty agreement, interest rate, effective percentage Royalty Agreement, Interest Rate, Effective Percentage Royalty Agreement, Interest Rate, Effective Percentage Variable Redemption, Remainder of Fiscal Year Through Year Four Variable Redemption, Remainder of Fiscal Year Through Year Four [Member] Variable Redemption, Remainder of Fiscal Year Through Year Four Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] 2033 Notes Initial Purchasers 2033 Notes Initial Purchasers [Member] 2033 Notes Initial Purchasers Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Potential Fixed Monetary Amount, Cash or stock at our sole discretion Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion Potential milestone fixed monetary amount settlement in cash or stock at sole discretion. All Adjustments to Compensation All Adjustments to Compensation [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Preferred stock, liquidation preference, value Preferred Stock, Liquidation Preference, Value Accounts Receivable Accounts Receivable [Member] Income Statement [Abstract] Income Statement [Abstract] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Debt Conversion Terms One Debt Conversion Terms One [Member] Debt Conversion Terms One Issuance of common stock under employee stock purchase plan ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Variable Redemption Price Component [Domain] Variable Redemption Price Component [Domain] Variable Redemption Price Component [Domain] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] City Area Code City Area Code Geographical Risk Geographic Concentration Risk [Member] Noncash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Collaborative Arrangement Collaborative Arrangement [Member] Estimated Fair Values Debt Instrument, Fair Value Disclosure Name Forgone Recovery, Individual Name Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Entity [Domain] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Research and Development, Contract to Perform for Others [Table] Research and Development, Contract to Perform for Others [Table] Minimum threshold percentage of aggregate principal by trustee or holders Minimum Threshold Percentage Of Aggregate Principal By Trustee Or Holders Minimum threshold percentage of aggregate principal by trustee or holders. Customer C Customer C [Member] Customer C. Cash Equivalents And Marketable Securities [Abstract] Cash Equivalents And Marketable Securities [Abstract] Cash equivalents and marketable securities. Issuance of common stock under employee stock purchase plan (ESPP) Stock Issued During Period, Value, Employee Stock Purchase Plan Proceeds from issuance of 2033 Notes /2031 Notes Proceeds from Convertible Debt Assumed conversion of 2033 Notes Assumed Conversion Of Two Thousand Thirty Three Notes [Member] Assumed Conversion Of Two Thousand Thirty Three Notes Other assets Increase (Decrease) in Other Operating Assets Organization and Description of Business Nature of Operations [Text Block] Issuance of preferred stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Research and Development Services Research and Development Services [Member] Research and Development Services Two Thousand Twenty Three Shelf Registration Statement and ATM Agreement Two Thousand Twenty Three Shelf Registration Statement and ATM Agreement [Member] Two Thousand Twenty Three Shelf Registration Statement and ATM Agreement Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total stock-based compensation Share-Based Payment Arrangement, Expense Stanford License Agreement Stanford License Agreement [Member] Stanford license agreement. Amortized Cost Basis Cash Equivalents, at Carrying Value Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Subsequent Event Type [Domain] Subsequent Event Type [Domain] Series A Cumulative Convertible Participating Preferred Stock Stockholders' Equity, Policy [Policy Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Unrealized loss on available-for-sale securities Unrealized (loss) gain on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Issuance costs and discounts associated with 2033 Notes/2031 Notes Payments of Debt Issuance Costs Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Accrued commercial Accrued Commercial Liabilities, Current Accrued commercial liabilities. Total Shareholder Return Amount Total Shareholder Return Amount Number of business segments Number Of Business Segments Number of business segments. Total cash equivalents and marketable securities, unrealized gains Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Current, Before Tax Repurchase of restricted stock unit (RSU) shares to satisfy tax withholding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Liability Liabilities, Fair Value Disclosure [Abstract] Schedule of Aggregate Face Values and Fair Values of Notes Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Research and development Total segment research and development Research and Development Expense Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] 2029 Long-Term Debt, Maturity, Year Three Financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Royalty obligation debt issuance costs Royalty Obligation, Debt Issuance Costs Royalty obligation debt issuance costs. Original share issued price (in dollars per share) Shares Issued, Price Per Share Premium over last reported sale price percentage Option Indexed to Issuer's Equity, Premium, Percentage Sale of stock premium over last reported sale price percentage. Financial Instruments Financial Instruments [Domain] Revenue, remaining performance obligation, sales milestone payment Revenue, Remaining Performance Obligation, Sales Milestone Payment Revenue, Remaining Performance Obligation, Sales Milestone Payment Other income Other Income Underlying Securities Award Underlying Securities Amount Comprehensive loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Issuance of preferred stock, net of issuance costs Stock Issued During Period, Value, New Issues Royalty percentage, maximum Revenue, Royalty Percentage Revenue, Royalty Percentage 2021 And 2020 Capped Call Transactions 2021 And 2020 Capped Call Transactions [Member] 2021 And 2020 Capped Call Transactions Preferred Stock Preferred Stock [Member] Inventories Increase (Decrease) in Inventories Transactions with noncontrolling interests Proceeds from (Payments to) Noncontrolling Interests Segment Reporting [Table] Segment Reporting [Table] Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant [Member] Acoramidis for ATTR-CM. Net loss Temporary Equity, Net Income Variable Redemption Price Component [Axis] Variable Redemption Price Component [Axis] Variable Redemption Price Component Sale of stock, aggregate offering amount Sale Of Stock, Aggregate Offering Amount Sale Of Stock, Aggregate Offering Amount Schedule of Components of Lease Cost Lease, Cost [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Convertible preferred stock, redemption price, percentage Convertible Preferred Stock, Redemption Price, Percentage Convertible Preferred Stock, Redemption Price, Percentage Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] APAC Asia Pacific [Member] Current Fiscal Year End Date Current Fiscal Year End Date Deferred royalty obligation, current Deferred Royalty Obligation, Current Deferred Royalty Obligation, Current Noncash interest expense on deferred royalty obligations Noncash interest expense on deferred royalty obligations Noncash interest expense on deferred royalty obligations Noncash Interest Expense On Deferred Royalty Obligations Noncash Interest Expense On Deferred Royalty Obligations Convertible preferred stock, threshold percentage of stock price trigger Convertible Preferred Stock, Threshold Percentage of Stock Price Trigger Convertible Preferred Stock, Threshold Percentage of Stock Price Trigger Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Issuance of noncontrolling interests Temporary Equity, Stock Issued During Period, Value, New Issues Gondola Bio, LLC Gondola Bio Llc [Member] GondolaBio, LLC. Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Issuance of shares under equity compensation plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Finite-lived intangible asset, expected amortization, thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Five Estimated fair value of deferred royalty obligation under funding agreement, net embedded derivative liability Deferred Royalty Obligation Under Funding Agreement Net of Embedded Derivative Liability, Fair Value Disclosure Deferred royalty obligation under funding agreement net of embedded derivative liability, fair value disclosure. Seller Parties Seller Parties [Member] Seller parties. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] BBP-418 for LGMD2I/R9 BBP 418 for LGMD2I/R9 [Member] BBP 418 for LGMD2I/R9. Measure: Measure [Axis] Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Accrued rebates and other related costs Accrued Rebates And Other Related Costs, Current Accrued rebates and other related costs. Treasury stock (in shares) Beginning balance (in shares) Ending balance (in shares) Shares Repurchased (in shares) Treasury Stock, Common, Shares Equity Components Equity Components [Axis] Related Party Related Party [Member] Entity Interactive Data Current Entity Interactive Data Current Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Deferred Royalty Obligations [Table] Deferred Royalty Obligations [Table] Deferred Royalty Obligations. Entity Small Business Entity Small Business Variable Rate Component [Domain] Variable Rate Component [Domain] Preferred Stock, Dividend Rate, Terms [Domain] Comprehensive loss attributable to BridgeBio Comprehensive Income (Loss), Net of Tax, Attributable to Parent Repurchase of restricted stock unit (RSU) shares to satisfy tax withholding, (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Sixth Street Purchaser Sixth Street Purchaser [Member] Sixth Street Purchaser Royalty obligation debt discount and issuance costs paid in cash Royalty Obligation Debt Discount and Issuance Costs Royalty obligation debt discount and issuance costs. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Other Assets, Noncurrent Royalty interest payments equal to cap amount Royalty Interest Payments Equal to Cap Amount Royalty interest payments equal to cap amount. Document Type Document Type Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Repayments of deferred royalty obligations Repayments of deferred royalty obligations Payment Of Deferred Royalty Obligation Repayment of deferred royalty obligation. Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Work in process Inventory, Work in Process, Gross Canada CANADA Loss before income taxes Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Accretion of preferred stock Temporary Equity, Accretion to Redemption Value, Adjustment Commitments and contingencies (Note 7) Commitments and Contingencies Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Concentration of Credit Risk and Other Risks and Uncertainties Concentration Of Credit Risk And Other Risks And Uncertainties [Policy Text Block] Concentration of credit risk and other risks and uncertainties. Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Finite-lived intangible asset, expected amortization, year four Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Alexion License Agreements Alexion License Agreements [Member] Alexion license agreements. Executive Category: Executive Category [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Liabilities, Redeemable Convertible Noncontrolling Interests and Stockholders’ Deficit Liabilities and Equity [Abstract] Inventories Total inventories Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount 2020 Capped Call Transactions 2020 Capped Call Transactions [Member] Capped call transactions. Eidos Eidos Therapeutics Inc. [Member] Eidos Therapeutics, Inc. Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Issuance costs associated with royalty obligation under Royalty Purchase Agreement Issuance Costs Associated With Royalty Obligation Under Royalty Purchase Agreement Issuance Costs Associated With Royalty Obligation Under Royalty Purchase Agreement PEO Name PEO Name Customer E Customer E [Member] Customer E. Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Accounts payable Increase (Decrease) in Accounts Payable Other accrued liabilities Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Debt Instrument Debt Instrument [Axis] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Total lease costs Lease, Cost Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share) Earnings Per Share, Basic In-Licensing And Other Research And Development Agreements [Abstract] In-Licensing And Other Research And Development Agreements [Abstract] In-licensing and other research and development agreements. Percentage of royalty payment equal to annual cap Percentage Of Royalty Payment Equal To Annual Cap Percentage of royalty payment equal to annual cap. Total current assets Assets, Current Insider Trading Arrangements [Line Items] 2027 Notes, 2029 Notes, 2031 Notes and 2033 Notes Long-Term Debt, Excluding Current Maturities Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Less amounts representing interest Long-Term Debt, Maturity, Less Amounts Representing Interest Long-Term Debt, Maturity, Less Amounts Representing Interest Schedule of Share Repurchase Transactions with Respect to the Notes Class of Treasury Stock [Table Text Block] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Advertising Expense Advertising Cost [Policy Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover Cover [Abstract] Debt instrument option to purchase additional notes Debt Instrument, Option To Purchase Additional Notes Debt instrument option to purchase additional notes. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary of significant accounting policies. 2033 Notes, net 2033 Convertible Senior Notes [Member] 2033 Convertible Senior Notes Estimated shares issuable under the ESPP Estimated Shares Issuable Employee Stock Purchase Plan [Member] Estimated shares issuable employee stock purchase plan. Percentage of concentration risk Concentration Risk, Percentage Equity Awards Adjustments Equity Awards Adjustments [Member] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Accrued research and development liabilities Increase Decrease In Accrued Research And Development Liabilities Increase (decrease) in accrued research and development liabilities. Proceeds from issuance of preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Other liabilities Increase (Decrease) in Other Operating Liabilities Other income, net Other Nonoperating Income (Expense) Finite-lived intangible asset, expected amortization, year five Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five Total BridgeBio Stockholders’ Deficit Parent [Member] Total cash equivalents and marketable securities , unrealized losses Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Cash Equivalents And Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Current, Before Tax Gondola Bio, LLC Gondola Bio Limited Liabilty Company [Member] Gondola bio limited liabilty company. Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Share Repurchase Program Share Repurchase Program [Axis] Class of Stock [Domain] Class of Stock [Domain] Preferred stock, dividend payment, variable rate Preferred Stock, Dividend Payment, Variable Rate Preferred Stock, Dividend Payment, Variable Rate Operating cash flows for finance lease Finance Lease, Interest Payment on Liability Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Income Taxes Income Tax Disclosure [Text Block] Schedule Of Cash And Cash Equivalents [Table] Cash and Cash Equivalent [Table] Accounts payable Accounts Payable, Current Other noncash adjustments, net Other Noncash Income (Expense) 2031 Lessee, Operating Lease, Liability, to be Paid, Year Five Accrued Amount, Total Potential Milestone Accrued Settlement Amount Potential milestone accrued settlement amount. Accretion of preferred stock Accretion of preferred stock Preferred Stock, Accretion of Redemption Discount Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Kyowa Kirin Co., Ltd Kyowa Kirin Co., Ltd [Member] Kyowa Kirin Co., Ltd Entity Filer Category Entity Filer Category Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Equity Method Investments and Joint Ventures [Abstract] Equity Method Investments and Joint Ventures [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Stock, Class of Stock [Table] Stock, Class of Stock [Table] Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Schedule of Potential Milestone Amounts and Accruals Schedule Of Potential Milestone Amounts And Accruals [Table Text Block] Schedule of potential milestone amounts and accruals. Senior Notes Senior Notes [Member] Entity Address, Address Line One Entity Address, Address Line One Operating lease right-of-use assets obtained in exchange for operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Share-Based Payment Arrangement, Disclosure [Abstract] Share-Based Payment Arrangement, Disclosure [Abstract] Fair value of amount outstanding Line of Credit Facility, Fair Value of Amount Outstanding Provision for (benefit from) income taxes Income Tax Expense (Benefit) Carrying value of deferred royalty obligations, net Carrying Value of Deferred Royalty Obligations, Net Carrying value of deferred royalty obligations, net. Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash Equivalents and Marketable Securities Cash, Cash Equivalent, and Marketable Security [Text Block] Proceeds from issuance of term loans after deducting debt discount and issuance costs Proceeds from Issuance of Term Loans After Deducting Debt Discount and Issuance Costs Proceeds from issuance of term loans after deducting debt discount and issuance costs. Statement [Table] Statement [Table] Proceeds from stock option exercises, net of repurchases Proceeds from Stock Options Exercised Interest income Investment Income, Interest Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain] Debt Instrument, Convertible Terms Of Conversion [Domain]